Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.
Tariot PN, Lopera FS, Ríos-Romenets S, Sink KM, Giraldo-Chica M, Acosta-Baena N, Villegas G, Espinosa A, Castaño ML, Muñoz C, Ospina P, Bocanegra Y, Tirado V, Henao E, Cardona E, Luna E, Lopez H, Sánchez G, Collazos MM, Alvarez S, Aguillón D, Hu N, Clayton D, Bittner T, Schneider A, Dolton M, Poon V, Nguyen J, Thomas RG, Schneider LS, Chen K, Su Y, Alexander RC, Quiroz YT, Cai Y, Xu YR, Ostaszewski B, Selkoe DJ, Ashton NJ, Denkinger MN, Jakimovich LJ, Doody RS, Langbaum JB, Reiman EM.
Tariot PN, et al. Among authors: rios romenets s.
Lancet Neurol. 2026 Feb;25(2):147-159. doi: 10.1016/S1474-4422(25)00426-0.
Lancet Neurol. 2026.
PMID: 41579901
Free article.
Clinical Trial.